Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases.

The presence of anti-nuclear antibodies (ANA) is a hallmark of systemic autoimmune rheumatic diseases (SARD). The indirect immunofluorescence (IIF) assay on HEp-2 cells is a commonly used test for the detection of ANA and was recently recommended as the screening test of choice by a task force of the American College of Rheumatology. However, up to 20% of serum samples from healthy individuals (HI) have been reported to have a positive ANA test, the majority of which are directed to the dense fine speckles 70 (DFS70) antigen. Even more important, the DFS IIF pattern has been reported in 33% of ANA positive HI, but not in ANA positive SARD sera. Since the intended use of the ANA HEp-2 test is to aid in the diagnosis of SARD, the reporting of anti-DFS70 antibodies and their associated pattern (DFS) as a positive test, significantly reduces the specificity and the positive likelihood of the ANA test. This has significant implications for diagnostic algorithms involving the detection of ANA. We summarize the current knowledge of anti-DFS70 antibodies and their impact on ANA testing. We also suggest a test algorithm which considers the DFS pattern and the presence of anti-DFS70 antibodies. In addition, we describe a novel method based on immunoadsorption of anti-DFS70 antibodies, which increases the specificity of the ANA HEp-2 test for SARD and which has the potential to overcome a significant limitation of the ANA HEp-2 assay.

[1]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[2]  M. Koenig,et al.  Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. , 2008, Autoimmunity reviews.

[3]  L. Andrade,et al.  Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. , 2011, Arthritis and rheumatism.

[4]  L. Chylack,et al.  Review: Age-related cataract: immunity and lens epithelium-derived growth factor (LEDGF). , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[5]  E. Chan,et al.  Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. , 2000, The Journal of allergy and clinical immunology.

[6]  S. Senju,et al.  Humoral immune response directed against LEDGF in patients with VKH. , 2001, Immunology letters.

[7]  T. Daniels,et al.  Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis , 2005, The Prostate.

[8]  Mario Plebani,et al.  Recent advances in diagnostic technologies for autoimmune diseases. , 2009, Autoimmunity reviews.

[9]  Marvin J Fritzler,et al.  Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. , 2008, Autoimmunity reviews.

[10]  Vidya Ganapathy,et al.  Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? , 2004, Arthritis and rheumatism.

[11]  A. Ballabio,et al.  Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results. , 2011, Autoimmunity reviews.

[12]  P. Schur,et al.  ANA screening: an old test with new recommendations , 2010, Annals of the rheumatic diseases.

[13]  R. Gittes,et al.  Autoantibodies in interstitial cystitis. , 1994, The Journal of urology.

[14]  R. Westhovens,et al.  Detection of anti-SSA antibodies by indirect immunofluorescence. , 2004, Clinical chemistry.

[15]  D. Pisetsky.  Antinuclear antibodies in healthy people: the tip of autoimmunity's iceberg? , 2011, Arthritis research & therapy.

[16]  P. Vermeersch,et al.  Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. , 2011, Autoimmunity reviews.

[17]  S. Platzgummer,et al.  Antibodies to the Lens and Cornea in Anti‐DFS70‐Positive Subjects , 2007, Annals of the New York Academy of Sciences.

[18]  Michael Mahler,et al.  Epitope specificity and significance in systemic autoimmune diseases , 2010, Annals of the New York Academy of Sciences.

[19]  Y. Muro,et al.  High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody–positive patients with autoimmune rheumatic disease , 2008, Lupus.

[20]  Marvin J Fritzler,et al.  The antinuclear antibody test: last or lasting gasp? , 2011, Arthritis and rheumatism.

[21]  Y. Muro,et al.  HLA-associated production of anti-DFS70/LEDGF autoantibodies and systemic autoimmune disease. , 2006, Journal of autoimmunity.

[22]  E. De Clercq,et al.  LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells* , 2003, Journal of Biological Chemistry.

[23]  Giulio Iannello,et al.  Novel opportunities in automated classification of antinuclear antibodies on HEp-2 cells. , 2011, Autoimmunity reviews.

[24]  Yasushi Tomita,et al.  Anti-DFS70 antibodies in 597 healthy hospital workers. , 2004, Arthritis and rheumatism.

[25]  L. Andrade,et al.  The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. , 2005, The Journal of rheumatology.

[26]  D. P. Singh,et al.  Detection of Cytotoxic Anti-LEDGF Autoantibodies in Atopic Dermatitis , 2002, Autoimmunity.

[27]  Rico Hiemann,et al.  Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. , 2009, Autoimmunity reviews.